Skip to content
Screener

Other Income (Expense) at other companies

Eli Lilly logo
Eli LillyLLY
$269M+399%
Corcept Therapeutics logo
Corcept TherapeuticsCORT
$4.63M-7.7%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-$3.98M-103%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1M-50.0%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
-$468K-127%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$12.53M-14.3%

Other financials

Income statement

See full
Revenue$92.1M+28.7%
Gross profit$79.6M+33.4%
Operating income$5.2M+15.4%
Net income-$31.1M-1,513%
EPS (diluted)-$0.18-1,700%

Balance sheet

See full
Cash & equivalents$121.7M+105%
Total debt$289.4M+12.5%
Total equity-$9.7M+49.6%
Total assets$411.9M+23.1%

Cash flow

See full
Operating cash flow$8.3M+4,440%
CapEx$131.0K
Free cash flow-$29.1M

Valuation

See full
Market cap$1.27B+44.5%
Enterprise value$1.44B+33.5%
P/S3.8×+0.2×

Profitability

See full
Gross margin86.6%+4.3pp
Operating margin10.9%+8.4pp
Net margin-5.1%-1.9pp

Returns & leverage

See full
Return on equity-209.8%
Debt / equity19.9×
Current ratio1.4×-0.5×

Where this comes from

Reported directly by Xeris Biopharma Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001867096-26-000065
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Interest and other income1,4559482,6572,123
Loss on debt extinguishment, net(30,782)(30,782)
Interest expense(6,947)(7,358)(13,831)(14,663)
Total other expense(36,274)(6,410)(41,956)(12,540)
Net loss before income taxes(31,101)(1,928)(28,867)(11,148)
Income tax benefit
Net loss$(31,101)$(1,928)$(28,867)$(11,148)
Other comprehensive income (loss), net of tax:

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Xeris Biopharma Holdings, Inc.'s other income (expense)?
Xeris Biopharma Holdings, Inc. (XERS) reported other income (expense) of -$36.27M in Q2 2026.
How has Xeris Biopharma Holdings, Inc.'s other income (expense) changed year-over-year?
Xeris Biopharma Holdings, Inc.'s other income (expense) decreased by 465.9% year-over-year, from -$6.41M to -$36.27M.
What is the long-term trend for Xeris Biopharma Holdings, Inc.'s other income (expense)?
Over 3 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s other income (expense) has grown at a 47.6% compound annual growth rate (CAGR), from -$7.57M to -$24.34M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about Xeris Biopharma Holdings, Inc.'s other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude